MX2024001834A - Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12. - Google Patents
Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12.Info
- Publication number
- MX2024001834A MX2024001834A MX2024001834A MX2024001834A MX2024001834A MX 2024001834 A MX2024001834 A MX 2024001834A MX 2024001834 A MX2024001834 A MX 2024001834A MX 2024001834 A MX2024001834 A MX 2024001834A MX 2024001834 A MX2024001834 A MX 2024001834A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- bladder cancer
- adc
- bind
- nmibc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233048P | 2021-08-13 | 2021-08-13 | |
| US202163242380P | 2021-09-09 | 2021-09-09 | |
| US202263328441P | 2022-04-07 | 2022-04-07 | |
| PCT/US2022/074897 WO2023019236A1 (en) | 2021-08-13 | 2022-08-12 | Methods for treating non-muscle invasive bladder cancer (nmibc) with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001834A true MX2024001834A (es) | 2024-05-15 |
Family
ID=85201025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001834A MX2024001834A (es) | 2021-08-13 | 2022-08-12 | Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250135020A1 (enExample) |
| EP (1) | EP4384279A4 (enExample) |
| JP (1) | JP2024534012A (enExample) |
| KR (1) | KR20240042109A (enExample) |
| AU (1) | AU2022328339A1 (enExample) |
| CA (1) | CA3223690A1 (enExample) |
| IL (1) | IL310175A (enExample) |
| MX (1) | MX2024001834A (enExample) |
| TW (1) | TW202315612A (enExample) |
| WO (1) | WO2023019236A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191201A1 (ru) | 2018-12-03 | 2022-01-26 | Эдженсис, Инк. | Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения |
| AU2024304180A1 (en) * | 2023-06-13 | 2026-01-08 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081653A1 (en) * | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| ES2874306T3 (es) * | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
| WO2021022172A1 (en) * | 2019-08-01 | 2021-02-04 | Incyte Corporation | A dosing regimen for an ido inhibitor |
| US20230270871A1 (en) * | 2020-06-19 | 2023-08-31 | Agensys, Inc. | Markers for use in methods for treating cancers with antibody drug conjugates (adc) |
-
2022
- 2022-08-12 KR KR1020247008395A patent/KR20240042109A/ko active Pending
- 2022-08-12 JP JP2024508641A patent/JP2024534012A/ja active Pending
- 2022-08-12 TW TW111130416A patent/TW202315612A/zh unknown
- 2022-08-12 CA CA3223690A patent/CA3223690A1/en active Pending
- 2022-08-12 MX MX2024001834A patent/MX2024001834A/es unknown
- 2022-08-12 AU AU2022328339A patent/AU2022328339A1/en active Pending
- 2022-08-12 IL IL310175A patent/IL310175A/en unknown
- 2022-08-12 EP EP22856829.1A patent/EP4384279A4/en active Pending
- 2022-08-12 US US18/682,886 patent/US20250135020A1/en active Pending
- 2022-08-12 WO PCT/US2022/074897 patent/WO2023019236A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL310175A (en) | 2024-03-01 |
| EP4384279A4 (en) | 2026-05-06 |
| WO2023019236A1 (en) | 2023-02-16 |
| US20250135020A1 (en) | 2025-05-01 |
| KR20240042109A (ko) | 2024-04-01 |
| AU2022328339A1 (en) | 2024-01-04 |
| EP4384279A1 (en) | 2024-06-19 |
| JP2024534012A (ja) | 2024-09-18 |
| CA3223690A1 (en) | 2023-02-16 |
| TW202315612A (zh) | 2023-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| CY1121023T1 (el) | Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες | |
| AR077998A1 (es) | Proteinas terapeuticas de union a dll4 | |
| EA201201120A1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 161p2f10b | |
| AU2018278311A1 (en) | IRE1 small molecule inhibitors | |
| CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
| MX2022001731A (es) | Tratamiento de cánceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteínas 191p4d12. | |
| WO2022026360A3 (en) | Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use | |
| EA201990839A1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7 | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| PH12022553333A1 (en) | Markers for use in methods for treating cancers with antibody drug conjugates (adc) | |
| MX2023004089A (es) | Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. | |
| PH12016500214A1 (en) | Antibody drug conjugates (adc) that bind to cd37 proteins | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| MX2022013882A (es) | Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos. | |
| WO2023133388A3 (en) | Methods for treating muscle invasive urothelial cancer or muscle invasive bladder cancer with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| PH12023550745A1 (en) | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| EP4670724A3 (en) | Anti-gprc5d monoclonal antibodies and uses thereof | |
| EA201491352A1 (ru) | Способ лечения рака груди | |
| AR131398A1 (es) | Tratamiento de enfermedades autoinmunitarias | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| AU2021344976A9 (en) | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| CO2023017609A2 (es) | Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso | |
| MX2023012766A (es) | Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. |